T helper 1–T helper 2 balance modulation (Th1–Th2 balance modulation)

The term “Th1–Th2 balance modulation” refers not to a single molecular target but rather to the therapeutic manipulation of the relative activities of two major subsets of CD4+ T-helper lymphocytes—T helper type 1 (Th1) cells and T helper type 2 (Th2) cells. These subsets are defined by their distinct cytokine secretion profiles: Th1 cells produce interferon-gamma (IFN‑γ), interleukin‐12 (IL‐12), and tumor necrosis factor-beta, promoting cellular immunity against intracellular pathogens such as viruses and some bacteria; Th2 cells secrete interleukins such as IL‐4, IL‐5, and IL‐13, supporting humoral immunity against extracellular parasites but also driving allergic responses when dysregulated. A healthy immune system maintains an appropriate functional equilibrium between these two arms—a disruption can lead either to autoimmune/inflammatory diseases (excessive Th1) or allergic/atopic conditions (excessive Th2) [1][3]. The “modulation” aspect involves interventions aimed at restoring this physiological equilibrium using drugs that influence relevant cytokines/transcription factors directly or indirectly via lifestyle changes such as diet/exercise [6]. Because this is an immunological concept/process rather than a discrete molecular entity like a receptor/enzyme/protein complex—and because it encompasses multiple molecules/cell types—it is not considered an individual druggable target in standard pharmacological classification systems. In summary: “Th1–Th2 balance modulation” describes strategies aimed at adjusting the ratio/activity between these two critical arms of adaptive immunity rather than referring to any one molecule/receptor/protein itself. It is best classified under immune response regulation rather than any canonical molecular family.[3][6]

Other names

Th1/Th2 balanceT helper 1/T helper 2 cell balanceTh1 vs. Th2 immunityModulation of T-helper cell polarization

Drugs modulate the immune system by shifting the polarization of CD4+ T cells toward either a Th1 or Th2 phenotype through effects on cytokine signaling pathways—such as increasing IFN‑γ for a Th1 shift or increasing IL‑4/IL‑13 for a Th2 shift—or by inhibiting key transcription factors involved in lineage commitment (e.g., GATA3 for Th2)